Another company is being pulled into a class action over a fatal bus crash in NSW’s Hunter Valley, with infrastructure consulting firm AECOM planning a cross-claim against engineering firm GHD Australia.
Rebel Wilson posted claims to her 11 million Instagram followers that the lead actress in her directorial debut had complained about a producer’s harassment, while knowing the accusations were false, a defamation case alleges.
The receiver for Banksia Securities — the failed lender at the centre of a scandal-ridden class action — has argued a new case accusing him of serious misconduct is vexatious and wants a court to release him from the claims.
Builder Shinetec has argued $48 million paid to the developer of a $185 million project in Sydney by Bank of China under a standby letter of credit was money it lent to the collapsed developer, with a judge seeming to agree the sum would otherwise be a windfall.
The developers of an industrial-chic Melbourne apartment building have won a fight against the building’s owners corporation over a lease that allowed Vodafone to store telecommunications equipment on the roof.
A judge has clarified a warning he made to refer lawyers for Alvarez & Marsal to the legal watchdog after hearing of the hefty costs of complying with discovery orders won by rival EY, saying the threat wasn’t directed at counsel.
Mayfield Developments has argued the High Court should overturn a finding that NSW Ports was protected by derivative Crown immunity in entering allegedly uncompetitive agreements to privatise two ports, saying the decision could have “startling” consequences such as allowing the state to devise cartel arrangements.
A judge has allowed a class action over Isuzus that allegedly contained emissions cheat devices to send an opt out notice to group members that includes a warning that if they sell their cars, they may “lose some or all of the money” they could receive in any settlement.
Baker McKenzie has appointed a new special counsel to join the law firm’s private equity practice group in its Sydney office.
Pharmaceutical giant Johnson & Johnson has denied knowingly selling alleged ineffective medications under its Benadryl, Sudafed and Codral brands, saying research indicated the phenylephrine-containing products worked.